Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04370015
Other study ID # 16082019
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 15, 2020
Est. completion date October 15, 2020

Study information

Verified date May 2020
Source Services Institute of Medical Sciences, Pakistan
Contact Saira Burney, FRCP (Edin)
Phone 923014226617
Email dr_syra@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Healthcare personnel are at an increased risk of exposure to SARS-CoV-2 infection while handling such patients. Currently, there is no treatment available for SARS-CoV-2 and stringent preventive measures are advised to avoid or minimize risk of exposure to healthcare workers. There are in vitro studies available which show inhibition of corona virus by hydroxychloroquine, a widely-used agent against malaria and certain autoimmune conditions and of low-cost and limited toxicity. However, evidence regarding its effects in patients is limited. We plan to conduct a randomized controlled trial to evaluate the safety and potential prophylactic efficacy of hydroxychloroquine in preventing secondary SARS-CoV-2 infection among healthcare workers at high-risk of exposure while managing such patients.


Description:

An interventional randomised control trial that will include 374 participants who will be healthcare workers at variable risks of exposure to SARS-CoV-2 while managing patients both suspected and confirmed with COVID-19 infection.Each participant will undergo detailed clinical evaluation to confirm eligibility, complete blood count, retinal imaging and ECG rhythm lead at baseline. A nasopharyngeal swab for reverse-transcriptase-polymerase chain reaction (RT-PCR) will also be taken. The enrolled participants will be randomised to two treatment arms with the experimental arm receiving Tab.Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400mg weekly for 11 weeks. The placebo comparator arm will receive 2 tablets twice daily on day 1 followed by 2 tablets weekly for 11 weeks. The participants will be followed up via phone call weekly to ensure drug compliance, occurrence of drug-related side effects or respiratory symptoms. The final visit 4 will mark the end of study at 12 weeks from randomisation when a repeat nasopharyngeal swab for SARS-CoV-2 RT-PCR will be taken.The primary outcome measures will be prevention of SARS-CoV-2 infection as determined by a negative RT-PCR in the experimental arm at the end of 12 weeks and HCQ safety as determined by occurrence of adverse events.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 374
Est. completion date October 15, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Adult healthcare workers all genders = 18 to = 60 years of age upon study consent.

- Healthcare workers (doctors and nurses) at Services hospital, Lahore considered work at high-risk of SARS-CoV-2 exposure (defined below):

- Healthcare workers in Corona triage areas.

- Healthcare workers in Corona Isolation Units.

- Healthcare workers in Corona ICUs.

- Healthcare workers in general medical wards.

- Healthcare workers in general surgical wards.

- Healthcare workers in other units not directly dealing with suspected Corona patients e.g. Endocrinology department

- Afebrile with no constitutional symptoms.

- No household contact with confirmed active SARS-CoV-2 infection in the last 3 weeks.

- Negative PCR at visit 0.

- Willing and able to comply with scheduled visits, treatment plan, and other study procedures.

- Willing to not take any other medicines especially fluoroquinolones and macrolides for the duration of study.

- Signed informed consent, demonstrating that the subject understands the interventions required for the study and the purpose of the study.

Exclusion Criteria:

- Participation in other investigational clinical trials for the treatment or prevention of SARS-CoV-2 infection within 30days.

- Subjects unwilling to practice at least one highly effective method of birth control for the duration of the study.

- Having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

- Having H/O skin disorders e.g. dermatitis, psoriasis or porphyria.

- Taking any of the following medication:

- Anti-arrythmic agents including digoxin.

- GI drugs including antacids, proton-pump inhibitors, cimetidine.

- Anti-cancer treatment including methotrexate, cyclosporin.

- Anti-diabetic agents including insulin.

- Corticosteroids.

- Drugs causing QT interval prolongation especially antidepressants, anti-epileptics and macrolides.

- Drugs affecting electrolyte balance including diuretics, laxatives.

- Drug allergies: 4-Aminoquinolines.

- Pre-existing retinopathy/maculopathy of the eye.

- Known chronic liver disease or cirrhosis, including hepatitis B and/or untreated hepatitis.

- Previous history of severe hypoglycaemia.

- Known case of renal disease.

- Untreated or uncontrolled active bacterial, fungal infection.

- Known or suspected active drug or alcohol abuse.

- Women who are pregnant or breastfeeding.

- Known hypersensitivity to any component of the study drug.

- A known history of prolonged QT syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of Long QT Syndrome).

- Known H/O respiratory disorders e.g. asthma, chronic obstructive pulmonary disease.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxychloroquine
Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
Placebo oral tablet
• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Services Institute of Medical Sciences, Pakistan

Outcome

Type Measure Description Time frame Safety issue
Primary Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period Negative RT-PCR for SARS-CoV-2 both at baseline and at end of 12 weeks in experimental arm From date of randomization until study completion 12 weeks after treatment initiation
Primary Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment To assess the presence or absence of side effects from HCQ treatment. From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation
Secondary Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR Symptomatic infection by SARS-CoV-2 defined as cough, dyspnea, fever, myalgia, arthralgia or rhinorrhea. From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation
Secondary Clinical disease severity in confirmed SARS-CoV-2 participants Disease severity including i) asymptomatic. ii) Mild symptoms but ambulatory. iii) Moderate symptoms requiring hospitalisation. iv) severe symptoms requiring ICU care and oxygen. v) Severe symptoms requiring assisted mechanical ventilation. vi) Death. From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation
Secondary Incidence of any acute respiratory infection Symptomatic non-COVID viral infection (any other acute respiratory illness with fever but without evidence of epidemiological risk factors such as close contact with SARS-CoV-2 positive patient or travel to or residence in high-risk area). From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A